-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Dr.
Krushna Patra
Only about 11% of people survive 5 years
after advanced pancreatic cancer is discovered.
The success rate of pancreatic cancer treatment is so low due to its late detection and incomplete understanding
of the course of disease development.
Scientists are working in multiple directions to understand the events
that lead to the development of pancreatic cancer.
At the University of Cincinnati, Krushna Patra's lab focuses on studying how genetic abnormalities, or genetic mutations,
are involved in these processes.
One such project being done in Patra's lab was recently funded by the National Cancer Institute Merit Award from the National Institutes of Health
.
Dr.
Patra is the first researcher
at the University of California to receive this prestigious award.
In contrast to traditional five-year research grants, the R37-MERIT Award provides an opportunity
for long-term grant support for promising early-stage researchers like Patra.
Patra has studied a number of genetic abnormalities associated with pancreatic cancer, including a gene
called GNAS.
The daily function of the GNAS gene is to maintain glucose levels in the body and assist in normal development, but when mutated, it becomes overactive and leads to cancer
.
GNAS mutations are present in about 8 to 9 percent of all advanced pancreatic cancers, but if other mutations are present in the lesion, it plays a greater role
in cancers that develop from pancreatic cysts.
Patra, a researcher at the University of Cincinnati Cancer Center, said: "Pancreatic cysts are similar to ovarian cysts in that they have the potential to develop into full-blown cancer, while GNAS mutations are found
in 50 to 60 percent of precancerous growth.
"
Cystic pancreatic tumors are very common in healthy people over the age of 70, Patra said, although not all cysts develop pancreatic cancer
.
But unlike other forms of pancreatic cancer, cystic pancreatic cancer can be detected at a very early stage, providing opportunities
for early intervention and treatment.
"If we understand the effects of this GNAS mutation, we can develop treatments or recommend surgical intervention in certain patients, which could prevent the worst outcomes
," Patra said.
Patra previously developed one of
the first animal models to replicate GNAS-mutated pancreatic cancer.
With this model, his team learned that when GNAS mutations are present in pancreatic cancer, it plays a role
in tumor initiation, progression, and maintenance.
Specifically, GNAS alters the metabolism of cancer cells, and GNAS-mutated pancreatic cancer develops a unique metabolic pathway
compared to other pancreatic cancer subtypes.
"This NCI award will allow us to recruit talented graduate students and postdocs in the lab to study how GNAS alters gene expression and alters mitochondrial structure and function to help tumors grow
," Patra said.
Patra said he is very excited about the future of the project and believes that the environment of the cancer center, UC School of Medicine and the research community is key
to his success.
"For example, the Cancer Metabolism, Signaling, and Therapeutics Affinity Group, which I jointly launched with the Plas, Czyk-Krzeska and Cunningham labs, provides a forum for collaborators to discuss research advances and refine projects that ultimately receive funding and publication," Patra said
.
I am also grateful to many other colleagues, including the PhD
.
Jarek Meller, Ken Greis, JJ Diao, Syed Ahmad and Davendra Sohal, their interactions are crucial
to the feasibility of this research project.
”
Patra said that as he continues his research, he is inspired by his scientific curiosity about a disease that is not yet fully understood, and his interactions with patients and their families to find advances
in treatment options.
"The patient approached me for help, which was really inspiring and told us that there was still a lot of work to be done
," he says.